From Mitochondrial Signal to Appetite Circuit

The short version

Chai Peptides is a literature desk, not a store — a place to read what the peer-reviewed research literature actually says about three peptides that sit inside appetite, satiety, and metabolic-signaling research: MOTS-c, tesamorelin, and tirzepatide. None of the three work the same way. MOTS-c is a tiny signal encoded inside mitochondrial DNA — the cell's energy-producing organelles — that appears to nudge how cells sense and use fuel. Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue, a synthetic peptide that turns up the body's own natural growth-hormone rhythm, with its clearest evidence in reducing deep abdominal (visceral) fat. Tirzepatide — the lead compound here — is a dual incretin-receptor agonist, engaging two separate gut-hormone receptors at once to quiet appetite and improve glucose handling.

What connects them isn't a shared mechanism; it's a shared question — how the body signals fullness, mobilizes stored fat, and regulates its own metabolic rate, and which of those signals a research compound can actually influence. This desk answers that with citations, not conclusions. We sell nothing, we give no medical advice, and we never state a human dose except exactly as a cited study used it.

What are research peptides?

Peptides are short chains of amino acids — the same building blocks that make up proteins, just far smaller. The three compounds on this desk occupy very different points on the research-to-approval spectrum. MOTS-c is a mitochondrial-derived peptide (MDP): encoded within the mitochondrial genome itself, it has never completed a human clinical trial and is sold exclusively as a laboratory research chemical ^[3]. Tesamorelin is an FDA-approved prescription medicine, but only for one specific population — adults with HIV-associated lipodystrophy — and any other use is off-label ^[7]. Tirzepatide is an FDA-approved prescription medicine with the broadest approved footprint of the three: type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea ^[12].

That spread matters. 'Research peptide' is not a single regulatory category — it can mean an investigational molecule with no human safety data, an approved drug being discussed for an off-label use, or an approved drug being discussed exactly as labeled. This site is careful to say which is which on every page, and it never recommends a dose for human use outside the context of a specific cited study.

How appetite, satiety, and metabolic signaling connect these three

• MOTS-c works from the inside out. As a mitochondrial-encoded peptide, it inhibits folate-cycle enzymes and activates AMPK — a cellular fuel-sensing switch — and a 2024 study identified casein kinase 2 (CK2) as a direct molecular target, with tissue-specific effects that improve skeletal-muscle glucose uptake ^[1]. It sits furthest from the clinic: every finding about its metabolic effects comes from cell and animal studies, with human data limited to biomarker associations ^[3].
• Tesamorelin works through the growth-hormone axis. By activating the GHRH receptor on the pituitary, it restores a more youthful pulsatile GH rhythm, which in turn drives the liver to make IGF-1 and promotes lipolysis concentrated in visceral fat. A 2026 meta-analysis of five randomized trials found significant reductions in visceral fat, trunk fat, and liver fat, alongside a gain in lean mass ^[6].
• Tirzepatide works through the gut-brain appetite axis. Its dual GIP/GLP-1 receptor engagement enhances glucose-dependent insulin secretion, slows gastric emptying, and — most consequentially for weight — acts on hypothalamic appetite circuits. In a head-to-head trial against semaglutide, tirzepatide produced significantly greater weight loss (-20.2% versus -13.7%) over 72 weeks ^[11].

Read individually or together, the three sketch three different entry points into the same broad research question: how the body decides how much to eat, how much fat to hold onto, and how to spend the energy it has. Compare them side by side.

A note on how this desk reads the evidence

The three compounds on this desk are not at the same evidentiary stage, and Chai Peptides says so plainly rather than smoothing it over. MOTS-c has no completed human efficacy trials — its research base is cell assays, rodent models, and observational human biomarker studies, and rodent doses (0.5-15 mg/kg/day in published work) cannot be extrapolated to a human dose ^[3]. Tesamorelin has a real, if narrow, regulatory approval and a growing base of randomized controlled trials and meta-analyses, but almost entirely within one population (HIV-associated lipodystrophy) ^[6][7]. Tirzepatide has the deepest evidence base of the three: multiple large, multi-thousand-participant phase 3 trials, across more than one indication, including a direct comparative trial against the prior standard of care ^[11][12]. Where a safety signal exists — gastrointestinal intolerance, gallbladder risk, or an entirely unregulated research-chemical supply chain — it appears in the text, not a footnote.